UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY **CAMDEN VICINAGE**

Document 2013-11

PageID: 65804

IN RE: VALSARTAN, LOSARTAN, AND IRBESARTAN PRODUCTS LIABILITY LITIGATION

MDL No. 2875

Honorable Robert B. Kugler, District Court Judge

This Document Relates to All Actions

[PROPOSED] ORDER **GRANTING DEFENDANTS' MOTION** TO COMPEL THE **PRODUCTION OF** TESTING AND OTHER **MATERIALS IN THE POSSESSION OF CLASS** EXPERT, DR. RON NAJAFI

ORDER

THIS MATTER, having been opened to the Court by Defendants for entry of an order compelling the production of testing and other materials in the possession of class expert, Dr. Ron Najafi, and the Court having considered the submissions and arguments of the parties, and for good cause shown;

IT IS on this day of , 2022, ORDERED as follows:

- Defendants' Motion to Compel is granted; and 1.
- 2. It is hereby ordered that Plaintiffs shall produce, within 14 days, the following materials:
 - a) The results of all testing performed by Emery Pharma and/or Valisure

Case 1:19-md-02875-RMB-SAK Document 2013-11 Filed 04/13/22 Page 2 of 2 PageID: 65805

on any valsartan drug substance or drug product;

b) The standard operating procedures, protocols, methods (including

validation) governing any such testing;

c) All reports and data generated related to any such testing;

d) The standard operating procedures, protocols, and policies related to

the sourcing and chain of custody for all samples of valsartan drug

substance or drug product received by Emery, including materials

identifying the patient to whom the medication was prescribed,

manufacturer, NDC, and batch/lot number;

e) All correspondence to, from, and among representatives of Emery

Pharma and/or Valisure regarding any testing performed on valsartan

or the citizen petition submitted to FDA on June 13, 2019; and

f) All invoices generated by Dr. Najafi and/or Emery Pharma related to

this testing.

Hon. Robert B. Kugler